AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Cytoplasmic dynein 2 intermediate chain 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8WVS4

UPID:

DC2I1_HUMAN

Alternative names:

Dynein 2 intermediate chain 1; WD repeat-containing protein 60

Alternative UPACC:

Q8WVS4; Q9NW58

Background:

Cytoplasmic dynein 2 intermediate chain 1, also known as Dynein 2 intermediate chain 1 and WD repeat-containing protein 60, is a crucial component of the cytoplasmic dynein 2 complex. This protein complex is essential for the movement of cargos along microtubules within cilia and flagella, working in harmony with the intraflagellar transport system. It plays a significant role in retrograde ciliary protein trafficking and is vital for maintaining a functional transition zone.

Therapeutic significance:

Short-rib thoracic dysplasia 8 with or without polydactyly, a condition marked by skeletal abnormalities and potential non-skeletal involvement, is caused by variants affecting this gene. Understanding the role of Cytoplasmic dynein 2 intermediate chain 1 could open doors to potential therapeutic strategies for this spectrum of diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.